VONOPRAZAN- VERSUS PROTON-PUMP INHIBITOR-BASED THIRD-LINE 7-DAY SITAFLOXACIN-CONTAINING TRIPLE THERAPY FOR HELICOBACTER PYLORI: A PROSPECTIVE, RANDOMIZED TRIAL

被引：0
|
作者：
Sue, Soichiro
Shibata, Wataru
Kaneko, Hiroaki
Irie, Kuniyasu
Sasaki, Tomohiko
Kondo, Masaaki
Maeda, Shin
机构：
来源：
GASTROENTEROLOGY | 2018年 / 154卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1302
引用
收藏
页码：S927 / S928
页数：2
相关论文
共 50 条
  • [1] Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori
    Sue, Soichiro
    Shibata, Wataru
    Sasaki, Tomohiko
    Kaneko, Hiroaki
    Irie, Kuniyasu
    Kondo, Masaaki
    Maeda, Shin
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (04) : 686 - 692
  • [2] Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial
    Sue, Soichiro
    Ogushi, Marina
    Arima, Isao
    Kuwashima, Hirofumi
    Nakao, Satoshi
    Naito, Makoto
    Komatsu, Kazuo
    Kaneko, Hiroaki
    Tamura, Toshihide
    Sasaki, Tomohiko
    Kondo, Masaaki
    Shibata, Wataru
    Maeda, Shin
    HELICOBACTER, 2018, 23 (02)
  • [3] Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication
    Ang, Daphne
    Koo, Seok Hwee
    Chan, Yiong Huak
    Tan, Thean Yen
    Soon, Gaik Hong
    Tan, Chin Kimg
    Lin, Kenneth Weicong
    Krishnasamy-Balasubramanian, Jaydeesh-Khanna
    Wong, Yu Jun
    Kumar, Rahul
    Rajesh, R.
    Tan, Yiyuan
    Ong, Peng-Lan Jeannie
    Tan, Yi-Lyn Jessica
    Li, James Weiquan
    Kwek, Andrew Boon-Eu
    Ang, Tiing Leong
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (03) : 436 - 449
  • [4] A Prospective Randomized Trial With 7-Day Nitrofurantoin-Containing Regime for Third-Line Helicobacter pylori Eradication
    Hung, Ivan F.
    Hang, Sze
    Liu, Kevin
    Leung, Wai Keung
    GASTROENTEROLOGY, 2012, 142 (05) : S740 - S740
  • [5] Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori
    Bunchorntavakul, Chalermrat
    Buranathawornsom, Arunluk
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (12) : 3308 - 3313
  • [6] Duration of Proton-Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis
    Flores, Haydee B.
    Salvana, Angela
    Ang, Ena Lyn R.
    Estanislao, Norberto I.
    Velasquez, Marie Ellaine
    Ong, Janus
    Nolasco, Eulenia R.
    Daez, Ma Lourdes
    Banez, Virgilio
    GASTROENTEROLOGY, 2010, 138 (05) : S340 - S340
  • [7] Addition of clidinium-C to the 14-day proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication
    Seyyedmajidi, Mohammadreza
    Homapoor, Saba
    Zanganeh, Elahe
    Dadjou, Mohammad
    Nejad, Shahab Eskandari
    Galayeri, Mohammad Hadi Tajik
    Vafaeimanesh, Jamshid
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2016, 7 (02) : 78 - 81
  • [8] Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection
    Nagahara, A
    Miwa, H
    Yamada, T
    Kurosawa, A
    Ohkura, R
    Sato, N
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (03) : 417 - 421
  • [9] Meta-analysis:: duration of first-line proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication
    Fuccio, Lorenzo
    Minardi, Maria Eugenia
    Zagari, Rocco Maurizio
    Grilli, Diego
    Magrini, Nicola
    Bazzoli, Franco
    ANNALS OF INTERNAL MEDICINE, 2007, 147 (08) : 553 - 562
  • [10] Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy for Helicobacter pylori eradication
    Ye, Chen-Li
    Liao, Guo-Ping
    He, Shuai
    Pan, Yan-Na
    Kang, Ying-Bo
    Zhang, Zhong-Yi
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (05) : 443 - 455
12345